September 1, 2024
Medical Retina Articles
September 1, 2024
Upfront: How Far We've Come
By Peter K. Kaiser, MD
September 1, 2024
Choosing Treatment for Primary Vitreoretinal Lymphoma
By Elaine Binkley, MD, Farzad Jamshidi, MD, PhD
September 1, 2024
Intravitreal Chemotherapy for Retinoblastoma
By Vishal R. Raval, MD, Vidhi Bajpai, MS, Arun D. Singh, MD
September 1, 2024
Current Trials in Uveal Melanoma
By Yehonatan Weinberger, MD, Arun D. Singh, MD
September 1, 2024
New Drug Therapies for Benign Retinal Tumors
By Mary E. Aronow, MD
September 1, 2024
New Product Applications: At-home OCT Imaging Device Approved
By Karen Appold, contributing writer
September 1, 2024
Coding Q&A: Billing for Injectable Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
August 26, 2024
RHONE-X Highlights DME Disease Control and Durability with Faricimab
By Arshad M. Khanani, MD, MA, FASRS, Michael A. Singer, MD
July 25, 2024
Phase 2 LUNA Trial Data Presented at ASRS
July 25, 2024
Ellipsoid Zone Integrity at Baseline Predicts Geographic Atrophy Progression Rate
July 23, 2024
Two-year Data on Susvimo Reported at ASRS
July 17, 2024
Outcomes of Faricimab in DME Study Presented at ASRS
July 10, 2024
Optogenetic Therapy Shows Promise for Retinitis Pigmentosa
July 10, 2024
FDA Approves Anti-VEGF Biosimilar Drug
July 10, 2024
Vabysmo Prefilled Syringe Receives FDA Approval
July 10, 2024
APX3330 Shows Promise in Slowing DR Progression
July 10, 2024
Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study
July 10, 2024
27-gauge Vitrectomy Shows Comparable Outcomes to 25-gauge in Trial
July 10, 2024
Cardiovascular Health Linked to Lower Retinopathy Risk in US Adults
July 1, 2024
Initial UK Faricimab Real-world Outcomes Presented at ARVO
By Rochelle Nataloni, contributing writer
July 1, 2024
Clinical Implications of Associations Between Diabetic Retinopathy and Age-related Macular Degeneration
By Deborah Li, BA, Nicholas Fazio, BS, Michael Wolek, MD, et al.
July 1, 2024
Sickle Cell Drug Shows Promise in Stabilizing Vision in Rare Genetic Disease
June 24, 2024
Macular Telangiectasia: New Hope on the Horizon
By Thomas A. Albini, MD, Michael A. Singer, MD
June 1, 2024
Upfront: New Efforts to Halt Diabetic Eye Disease
By Peter K. Kaiser, MD
June 1, 2024
Coding: Medicare Considerations of Compounded Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
June 1, 2024
Controversies in Care: Chlorhexidine as an Alternative to Povidone-iodine for Antisepsis Before Intravitreal Injection
By Michael Colucciello, MD, Jason Fan, MD, PhD, Harry W. Flynn Jr., MD, et al.
May 1, 2024
New Product Applications: Lengthening the Time Between Treatments
By Karen Appold, contributing writer
May 1, 2024
Upfront: The Technological Intersection of Aviation and Retina
By Peter K. Kaiser, MD
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
New Product Applications: The First FDA-approved Topical Ocular Anesthetic Debuts
By Karen Appold, contributing writer
April 1, 2024
Improving Durability of Drugs in Wet AMD
By Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA
April 1, 2024
Subspecialty News April 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
Tyrosine Kinase Inhibitors for Wet AMD and Diabetic Retinopathy
By Nikhil Das, MD, Katherine E. Talcott, MD
April 1, 2024
Nesvategrast Fails to Meet Primary Efficacy Endpoint in DR:EAM Trial
By Jim Gallagher, managing editor
April 1, 2024
Broader VEGF Pathway Inhibition for Wet AMD
By Mark R. Barakat, MD, Mark P. Breazzano, MD
January 1, 2024
Clinical Trial Update January/February 2024
January 1, 2024
CONTROVERSIES IN CARE: Withdrawal of Anti-VEGF Agents in Neovascular AMD
By Michael Colucciello, MD, Anat Loewenstein, MD, MHA, Diana V. Do, MD
November 1, 2023
NEW PRODUCT APPLICATIONS: Drug Slows the Progression of Geographic Atrophy
By Karen Appold, contributing writer
November 1, 2023
Clinical Trial Update November/December 2023
October 1, 2023
Clinical Trial Update October 2023
October 1, 2023
Clinical Pearls for Newly Approved Treatments for GA
By Aamir A. Aziz, BS, Carl Danzig, MD
September 1, 2023
Bispecific Antibodies in Retina Therapies
By René Rückert, MD, MBA, Gemmy Cheung Chui Ming, FRCOphth, Marion R. Munk, MD, PhD, FEBO
September 1, 2023
CODING Q&A: Medicare Reimbursement for Discarded Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
September 1, 2023
Clinical Trial Update September 2023
July 1, 2023
Clinical Trial Update July/August 2023
April 1, 2023
Clinical Trial Update April 2023
February 1, 2023
SUBSPECIALTY NEWS: Methotrexate for vitreoretinal lymphoma, drugs for retinitis pigmentosa, AI technology in retina, and more.
By Rochelle Nataloni, contributing writer
July 1, 2022
The Impact of Pregnancy on Diabetic Retinopathy and Its Implications
By Kanika Seth, Matthew W. Russell, MD, Justin C. Muste, MD, et al.
July 1, 2022
Oral Drug Pipeline for Retinal Disease
By Charles DeBoer, MD, PhD, Suzanne Michalak, MD, Ehsan Rahimy, MD
July 1, 2022
Potential Implications of Silicone Oil From Syringes
By Gustavo B. Melo, MD, PhD, FASRS
July 1, 2022
UPFRONT: Retina Drug Shortages
By Peter K. Kaiser, MD
June 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy quality-of-life survey, Xipere launch, ophthalmic bevacizumab FDA application, and more.
By Rochelle Nataloni, contributing writer
April 1, 2022
The Current Landscape of Intravitreal Treatments for Neovascular AMD
By Matias Iglicki, MD, Anat Loewenstein, MD, MHA, Dinah Zur, MD
April 1, 2022
UPFRONT: Medical Therapy in a Time of War
By Peter K. Kaiser, MD
April 1, 2022
SUBSPECIALTY NEWS: FDA approves uveal melanoma treatment, sepofarsen fails to meet endpoints, and more.
By Rochelle Nataloni, contributing writer
March 1, 2022
Intraocular Inflammation Associated With Current and Prospective Therapies for Patients With Wet AMD
By Andreas M. Wingert, Jayanth Sridhar, MD
February 1, 2022
Faricimab Approved by the FDA for Wet AMD and DME
By Rochelle Nataloni, contributing writer
Advertisement
Recommendations
Advertisement